 | • レポートコード：MRC2307A0042 • 出版社/出版日：Transparency Market Research / 2023年5月 • レポート形態：英文、PDF、190ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Transparency Market Research社の当市場調査書によると、世界のがん生検市場規模が、2023年の247億ドルから2031年までに620億ドルに達し、予測期間中にCAGR（年平均成長率）11.4%で拡大すると予想されています。本書は、がん生検の世界市場を総合的に調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、価格分析、製品別（プラットフォーム・器具、キット・試薬、サービス）分析、種類別（組織生検、液体生検、その他）分析、用途別（乳癌、結腸直腸癌、子宮頸癌、肺癌、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ）分析、競争状況などの項目を掲載しています。なお、Abbott Laboratories、Becton, Dickinson and Company、F. Hoffmann-La Roche Ltd.、Hologic, Inc.、Danaher Corporation、Thermo Fisher Scientific, Inc.、Agilent Technologies, Inc.、Illumina, Inc.、Siemens Healthineers、GE Healthcare、Bio-Rad Laboratories, Inc.、Olympus Corporation、QIAGENなど、主要企業情報が含まれています。 ・序論 ・仮定・調査手法 ・エグゼクティブサマリー ・市場概要 ・主要インサイト ・価格分析 ・世界のがん生検市場規模：製品別 - プラットフォーム・器具の市場規模 - キット・試薬の市場規模 - サービスの市場規模 ・世界のがん生検市場規模：種類別 - 組織生検の市場規模 - 液体生検の市場規模 - その他種類の市場規模 ・世界のがん生検市場規模：用途別 - 乳癌における市場規模 - 結腸直腸癌における市場規模 - 子宮頸癌における市場規模 - 肺癌における市場規模 - その他用途における市場規模 ・世界のがん生検市場規模：地域別 - 北米のがん生検市場規模 - ヨーロッパのがん生検市場規模 - アジア太平洋のがん生検市場規模 - 中南米のがん生検市場規模 - 中東・アフリカのがん生検市場規模 ・競争状況 |
Cancer Biopsy Market – Scope of Report
TMR’s report on the global Cancer Biopsy Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Cancer Biopsy Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Cancer Biopsy Market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Cancer Biopsy market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the Cancer Biopsy.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the Cancer Biopsy. These serve as valuable tools for existing market players as well as for entities interested in participating in the Cancer Biopsy.
The report delves into the competitive landscape of the Cancer Biopsy. Key players operating in the global Cancer Biopsy Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Cancer Biopsy Market profiled in this report.
Key Questions Answered in Global Cancer Biopsy Market Report
• What is the sales/revenue generated by Cancer Biopsy across all regions during the forecast period?
• What are the opportunities in the Cancer Biopsy?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?
Cancer Biopsy Market – Research Objectives and Research Approach
The comprehensive report on the global Cancer Biopsy Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global Cancer Biopsy Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the Cancer Biopsy.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Cancer Biopsy Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Cancer Biopsy Market Analysis and Forecast, 2017-2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Cancer Prevalence & Incidence, by Region
5.2. Technological Advancements
5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
5.4. Reimbursement Scenario by Region/Globally
5.5. Value Chain Analysis
6. Global Cancer Biopsy Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017-2031
6.3.1. Platforms & Instruments
6.3.2. Kits & Reagents
6.3.3. Services
6.4. Market Attractiveness Analysis, by Product
7. Global Cancer Biopsy Market Analysis and Forecast, by Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Type, 2017-2031
7.3.1. Tissue Biopsies
7.3.1.1. Needle Biopsies
7.3.1.2. Surgical Biopsies
7.3.2. Liquid Biopsies
7.3.3. Others
7.4. Market Attractiveness Analysis, by Type
8. Global Cancer Biopsy Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017-2031
8.3.1. Breast Cancer
8.3.2. Colorectal Cancer
8.3.3. Cervical Cancer
8.3.4. Lung Cancer
8.3.5. Prostate Cancer
8.3.6. Skin Cancer
8.3.7. Blood Cancer
8.3.8. Kidney Cancer
8.3.9. Liver Cancer
8.3.10. Pancreatic Cancer
8.3.11. Ovarian Cancer
8.3.12. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Cancer Biopsy Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017-2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Cancer Biopsy Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product, 2017-2031
10.2.1. Platforms & Instruments
10.2.2. Kits & Reagents
10.2.3. Services
10.3. Market Value Forecast, by Type, 2017-2031
10.3.1. Tissue Biopsies
10.3.1.1. Needle Biopsies
10.3.1.2. Surgical Biopsies
10.3.2. Liquid Biopsies
10.3.3. Others
10.4. Market Value Forecast, by Application, 2017-2031
10.4.1. Breast Cancer
10.4.2. Colorectal Cancer
10.4.3. Cervical Cancer
10.4.4. Lung Cancer
10.4.5. Prostate Cancer
10.4.6. Skin Cancer
10.4.7. Blood Cancer
10.4.8. Kidney Cancer
10.4.9. Liver Cancer
10.4.10. Pancreatic Cancer
10.4.11. Ovarian Cancer
10.4.12. Others
10.5. Market Value Forecast, by Country, 2017-2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Type
10.6.3. By Application
10.6.4. By Country
11. Europe Cancer Biopsy Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017-2031
11.2.1. Platforms & Instruments
11.2.2. Kits & Reagents
11.2.3. Services
11.3. Market Value Forecast, by Type, 2017-2031
11.3.1. Tissue Biopsies
11.3.1.1. Needle Biopsies
11.3.1.2. Surgical Biopsies
11.3.2. Liquid Biopsies
11.3.3. Others
11.4. Market Value Forecast, by Application, 2017-2031
11.4.1. Breast Cancer
11.4.2. Colorectal Cancer
11.4.3. Cervical Cancer
11.4.4. Lung Cancer
11.4.5. Prostate Cancer
11.4.6. Skin Cancer
11.4.7. Blood Cancer
11.4.8. Kidney Cancer
11.4.9. Liver Cancer
11.4.10. Pancreatic Cancer
11.4.11. Ovarian Cancer
11.4.12. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Type
11.6.3. By Application
11.6.4. By Country/Sub-region
12. Asia Pacific Cancer Biopsy Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017-2031
12.2.1. Instruments
12.2.2. Kits & Reagents
12.2.3. Services
12.3. Market Value Forecast, by Type, 2017-2031
12.3.1. Tissue Biopsies
12.3.1.1. Needle Biopsies
12.3.1.2. Surgical Biopsies
12.3.2. Liquid Biopsies
12.3.3. Others
12.4. Market Value Forecast, by Application, 2017-2031
12.4.1. Breast Cancer
12.4.2. Colorectal Cancer
12.4.3. Cervical Cancer
12.4.4. Lung Cancer
12.4.5. Prostate Cancer
12.4.6. Skin Cancer
12.4.7. Blood Cancer
12.4.8. Kidney Cancer
12.4.9. Liver Cancer
12.4.10. Pancreatic Cancer
12.4.11. Ovarian Cancer
12.4.12. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Type
12.6.3. By Application
12.6.4. By Country/Sub-region
13. Latin America Cancer Biopsy Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017-2031
13.2.1. Platforms & Platforms & Instruments
13.2.2. Kits & Reagents
13.2.3. Services
13.3. Market Value Forecast, by Type, 2017-2031
13.3.1. Tissue Biopsies
13.3.1.1. Needle Biopsies
13.3.1.2. Surgical Biopsies
13.3.2. Liquid Biopsies
13.3.3. Others
13.4. Market Value Forecast, by Application, 2017-2031
13.4.1. Breast Cancer
13.4.2. Colorectal Cancer
13.4.3. Cervical Cancer
13.4.4. Lung Cancer
13.4.5. Prostate Cancer
13.4.6. Skin Cancer
13.4.7. Blood Cancer
13.4.8. Kidney Cancer
13.4.9. Liver Cancer
13.4.10. Pancreatic Cancer
13.4.11. Ovarian Cancer
13.4.12. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Type
13.6.3. By Application
13.6.4. By Country/Sub-region
14. Middle East & Africa Cancer Biopsy Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017-2031
14.2.1. Platforms & Instruments
14.2.2. Kits & Reagents
14.2.3. Services
14.3. Market Value Forecast, by Type, 2017-2031
14.3.1. Tissue Biopsies
14.3.1.1. Needle Biopsies
14.3.1.2. Surgical Biopsies
14.3.2. Liquid Biopsies
14.3.3. Others
14.4. Market Value Forecast, by Application, 2017-2031
14.4.1. Breast Cancer
14.4.2. Colorectal Cancer
14.4.3. Cervical Cancer
14.4.4. Lung Cancer
14.4.5. Prostate Cancer
14.4.6. Skin Cancer
14.4.7. Blood Cancer
14.4.8. Kidney Cancer
14.4.9. Liver Cancer
14.4.10. Pancreatic Cancer
14.4.11. Ovarian Cancer
14.4.12. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product
14.6.2. By Type
14.6.3. By Application
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2022
15.3. Company Profiles
15.3.1. Abbott Laboratories
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Becton, Dickinson and Company
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. F. Hoffmann-La Roche Ltd.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Hologic, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Danaher Corporation
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Thermo Fisher Scientific, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Agilent Technologies, Inc.
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Illumina, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Siemens Healthineers
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. GE Healthcare
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. Bio-Rad Laboratories, Inc.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Olympus Corporation
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. QIAGEN
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Product Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
Table 01: Global Cancer Biopsy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 02: Global Cancer Biopsy Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 03: Global Cancer Biopsy Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 04: Global Cancer Biopsy Market Value (US$ Mn) Forecast, by Tissue Biopsies, 2017-2031
Table 05: Global Cancer Biopsy Market Value (US$ Mn) Forecast, by Liquid Biopsies, 2017-2031
Table 06: Global Cancer Biopsy Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 07: North America Cancer Biopsy Market Value (US$ Mn) Forecast, by Country, 2017-2031
Table 08: North America Cancer Biopsy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 09: North America Cancer Biopsy Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 10: North America Cancer Biopsy Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 11: North America Cancer Biopsy Market Value (US$ Mn) Forecast, by Tissue Biopsies, 2017-2031
Table 12: North America Cancer Biopsy Market Value (US$ Mn) Forecast, by Liquid Biopsies, 2017-2031
Table 13: Europe Cancer Biopsy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 14: Europe Cancer Biopsy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 15: Europe Cancer Biopsy Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 16: Europe Cancer Biopsy Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 17: Europe Cancer Biopsy Market Value (US$ Mn) Forecast, by Tissue Biopsies, 2017-2031
Table 18: Europe Cancer Biopsy Market Value (US$ Mn) Forecast, by Liquid Biopsies, 2017-2031
Table 19: Asia Pacific Cancer Biopsy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 20: Asia Pacific Cancer Biopsy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 21: Asia Pacific Cancer Biopsy Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 22: Asia Pacific Cancer Biopsy Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 23: Asia Pacific Cancer Biopsy Market Value (US$ Mn) Forecast, by Tissue Biopsies, 2017-2031
Table 24: Asia Pacific Cancer Biopsy Market Value (US$ Mn) Forecast, by Liquid Biopsies, 2017-2031
Table 25: Latin America Cancer Biopsy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 26: Latin America Cancer Biopsy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 27: Latin America Cancer Biopsy Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 28: Latin America Cancer Biopsy Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 29: Latin America Cancer Biopsy Market Value (US$ Mn) Forecast, by Tissue Biopsies, 2017-2031
Table 30: Latin America Cancer Biopsy Market Value (US$ Mn) Forecast, by Liquid Biopsies, 2017-2031
Table 31: Middle East & Africa Cancer Biopsy Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 32: Middle East & Africa Cancer Biopsy Market Value (US$ Mn) Forecast, by Product, 2017-2031
Table 33: Middle East & Africa Cancer Biopsy Market Value (US$ Mn) Forecast, by Type, 2017-2031
Table 34: Middle East & Africa Cancer Biopsy Market Value (US$ Mn) Forecast, by Application, 2017-2031
Table 35: Middle East & Africa Cancer Biopsy Market Value (US$ Mn) Forecast, by Tissue Biopsies, 2017-2031
Table 36: Middle East & Africa Cancer Biopsy Market Value (US$ Mn) Forecast, by Liquid Biopsies, 2017-2031